NEW YORK (GenomeWeb) – Genomic Vision said today that it has signed an exclusive distribution agreement that will enable AmCare Genomics Laboratory to market its facioscapulohumeral muscular dystrophy diagnostic assay in China.
Financial and other terms of the deal were not disclosed.
David Del Bourgo, marketing and sales director of Genomic Vision, said in a statement that following a distribution deal with APG Bio earlier this year, the agreement "represents a second major milestone in our global strategy to enter new markets in Asia."
AmCare Genomics CEO Victor Wei Zhang said that it has a "large network and connections within the neurology and FSHD communities in China," which would enable it to raise "significant awareness among physicians and patients" about the FSHD test.
Genomic Vision develops tools for life sciences research and diagnostic solutions for the early detection of cancers and genetic diseases. It leverages a DNA molecular combing technology that enables it to identify genetic abnormalities.
FSHD is the third most prevalent muscular hereditary myopathy globally, Genomic Vision said, adding that an estimated 1 in 10,000 to 1 in 20,000 people are affected. In China, between 70,000 and 140,000 people have FSHD, Del Bourgo said.